2018-03-12
Dr. Frank Shen Has Joined EffPha

We are pleased to announce that Dr. Frank Shen has joined Efficient Pharma Management Corporate (EffPha) as the new President and CEO. Together with the founders of EffPha, Dr. Du-Shieng Chien and Dr. Yi-Wen Chu, Dr. Shen will lead EffPha team to provide a more comprehensive service with global standards for new drug development.
Since founded in 2009, EffPha has served more than 50 pharmaceuticals and biotech companies and successfully completed more than 200 drug development projects. EffPha attracts experts from different fields that have more than 25 years of experience working in global pharmaceutical companies to provide our clients with the most efficient plan for new drug development including assisting design and compiling technical and medical documents in CTD format that meet with different regulations. EffPha also established our own clinical operation team in 2015 to meet business needs. We now have the experience and are capable to conduct Phase I-III clinical studies. Through Dr. Shen’s extensive experience in global new drug development and data/statistical sciences, EffPha will be further enhanced to provide one-stop, end to end service to our clients from scientific evaluation to regulatory submission.
Dr. Shen served as the Vice President of Data & Statistical Sciences at AbbVie Inc. in the past seven years. In this capacity, Dr. Shen leads 400 quantitative scientists worldwide to support global drug discovery and development. Prior to joining AbbVie/Abbott in 2011, he was the co-founder of Roche Global Pharma Development Center in China (PDCC) based in Shanghai and Asia-Pacific Biometrics Head. During the five years in Shanghai, Dr. Shen not only led the establishment and enhancement of clinical capabilities in China with close interactions with the CFDA, but also served as the Project leader of Roche Asia-Pacific Actemra® development team that played a crucial role in bringing this humanized monoclonal antibody against IL-6 receptor from late-stage development (2008) to NDA filing (2010) and approval (2013) in China.
Prior to joining Roche, Dr. Shen spent 12 years at Bristol-Myers Squibb (BMS) where he was the Executive Director of Global Biometric Sciences. At the same time, Dr. Shen was also a member of both the BMS Clinical Science Committee and the Development Excellence Council that review clinical protocols and govern process in clinical operations. Before this, Dr. Shen started his career in the pharmaceutical industry with Wyeth-Ayerst Research as a Research statistician, and then moved to Merck & Co. as a manager of the Biometrics Research group.
With Dr. Shen’s extensive drug development experience as well as his good knowledge and relationship in the market of US, Asia-Pacific and China, Dr. Shen will lead EffPha to build up a complete service portfolio for drug development, and support Taiwan’s pharmaceuticals and biotech companies to work more closely with global partners and meet with global standards.